Arquivos do dia: Janeiro 20, 2022

Longevidade do reforço: dados revelam quanto tempo dura a proteção da terceira dose.

20 Jan, 2022 | 23:19h

Booster longevity: Data reveals how long a third shot protects – NPR

Relatório original: SARS-CoV-2 variants of concern and variants under investigation in England – U.K. Health Security Agency

---

Estudo de coorte retrospectiva de base populacional no Catar mostrou menor risco de infecção por Covid-19 após a vacina da Moderna em comparação com a da Pfizer–BioNTech.

20 Jan, 2022 | 23:17h

Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar – New England Journal of Medicine

 

Comentário no Twitter

In two matched retrospective cohort studies comparing BNT162b2 and mRNA-1273, both were highly effective at preventing hospitalization & death. Breakthrough infections were lower among those who received mRNA-1273 than those who received BNT162b2. https://t.co/wgkrzfLNHz pic.twitter.com/E8hXIDFqWW

— NEJM (@NEJM) January 19, 2022

 

---

Doença mais leve com a Ômicron: é o vírus ou é a imunidade pré-existente?

20 Jan, 2022 | 23:16h

Milder disease with Omicron: is it the virus or the pre-existing immunity? – Nature Reviews Immunology

---

Como a Ômicron se dissemina tão rápido? Uma alta carga viral não é a resposta – “Dados sobre níveis virais apontam para evasão imunológica como causa da transmissibilidade da variante.”

20 Jan, 2022 | 23:15h

How does Omicron spread so fast? A high viral load isn’t the answer – Nature

---

Função cardíaca é rapidamente recuperada em crianças com síndrome inflamatória multissistêmica (MIS-C) relacionada à COVID-19.

20 Jan, 2022 | 23:14h

Comunicado de imprensa: Heart function recovered quickly in children with COVID-19-related MIS-C condition – American Heart Association

Estudo original: Longitudinal Assessment of Cardiac Outcomes of Multisystem Inflammatory Syndrome in Children Associated With COVID‐19 Infections – Journal of the American Heart Association

---

Revisão breve | Fluvoxamina para pacientes ambulatoriais sintomáticos com COVID-19.

20 Jan, 2022 | 23:12h

Fluvoxamine for symptomatic outpatients with COVID-19 – Canadian Medical Association Journal

Conteúdos relacionados:

Fluvoxamine for Covid-19: What Prescribers and Pharmacists Need to Know.

Fluvoxamine for the early treatment of SARS-CoV-2 Infection: a review of current evidence.

RCT: Early treatment with fluvoxamine reduced the risk of emergency care and hospitalization among patients with COVID-19.

[Preprint] RCT: Fluvoxamine reduced the risk for ER visits and hospitalization among patients with Covid-19.

Opinion | Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? (It’s fluvoxamine).

Preliminary study shows fluvoxamine may reduce clinical deterioration in outpatients with symptomatic COVID-19

---

Amplo estudo observacional mostrou que pessoas com disfunção imunológica (HIV, transplante de órgão sólido, artrite reumatoide) estão sob risco aumentado de infecção por Covid-19 após a vacinação.

20 Jan, 2022 | 23:11h

Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US – JAMA Internal Medicine

---

Depois da Ômicron, poderíamos ter uma pausa. Talvez tenhamos.

20 Jan, 2022 | 23:10h

After Omicron, we could use a break. We may just get it – STAT

---

10 lições aprendidas com a pandemia de Covid-19.

20 Jan, 2022 | 23:09h

10 lessons I’ve learned from the Covid–19 pandemic – STAT

---

OMS afirma que a pandemia de Covid “está longe do fim”.

20 Jan, 2022 | 23:07h

Covid pandemic ‘nowhere near over,’ WHO says – CNN

---